Income statement revenue $989.71M (+19.9% YoY).Operating income $110.92M (-59.9% YoY).Pre-tax result $61.38M (-79.4% YoY).Net result $44.76M (-81.4% YoY).

ALDURAZYME: $43.54M (-22.9% YoY)
BRINEURA: $51.37M (+5.5% YoY)
GALAFOLD: $105.75M
KUVAN: $24.44M (-9.6% YoY)
NAGLAZYME: $135.26M (+5.0% YoY)
PALYNZIQ: $135.17M (+27.6% YoY)
POMBILITIOPFOLDA: $30.26M
ROCTAVIAN: $11.71M (+27.3% YoY)
Royalty And Other: $5.32M (-57.2% YoY)
VIMIZIM: $194.37M (-9.8% YoY)
VOXZOGO: $252.53M (+14.1% YoY)
Research and development: $206.95M
Selling, general and administrative: $395.55M
Intangible asset amortization: $73.49M
Other income, net: $3.28M
Other expense: $49.54M
Income tax expense: $16.62M (-71.0% YoY)

Loading financials

Income statement income statement flow. Revenue $989.71M. Net result $44.76M.

Income statement revenue $989.71M (+19.9% YoY).Operating income $110.92M (-59.9% YoY).Pre-tax result $61.38M (-79.4% YoY).Net result $44.76M (-81.4% YoY).

ALDURAZYME: $43.54M (-22.9% YoY)
BRINEURA: $51.37M (+5.5% YoY)
GALAFOLD: $105.75M
KUVAN: $24.44M (-9.6% YoY)
NAGLAZYME: $135.26M (+5.0% YoY)
PALYNZIQ: $135.17M (+27.6% YoY)
POMBILITIOPFOLDA: $30.26M
ROCTAVIAN: $11.71M (+27.3% YoY)
Royalty And Other: $5.32M (-57.2% YoY)
VIMIZIM: $194.37M (-9.8% YoY)
VOXZOGO: $252.53M (+14.1% YoY)
Research and development: $206.95M
Selling, general and administrative: $395.55M
Intangible asset amortization: $73.49M
Other income, net: $3.28M
Other expense: $49.54M
Income tax expense: $16.62M (-71.0% YoY)